Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms THEN
- 07 Sep 2017 Planned initiation date changed from 1 Dec 2016 to 1 Sep 2017.
- 07 Sep 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Aug 2016 New trial record